Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor-[beta] receptor I in head and neck cancer

Background Circulating tumor microemboli (CTM) are clusters of circulating tumor cells (CTCs), involved in metastasis, as also transforming growth factor-[beta] (TGF-[beta]). The purpose of this study was to verify their role in progression-free survival (PFS). Methods Blood from patients with local...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2017-11, Vol.39 (11), p.2283
Main Authors: Fanelli, Marcello Ferretti, Oliveira, Thiago Bueno, Braun, Alexcia Camila, Corassa, Marcelo, Abdallah, Emne Ali, Nicolau, Ulisses Ribaldo, da Silva Alves, Vanessa, Garcia, Daniel, Calsavara, Vinicius F, Kowalski, Luiz Paulo, Chinen, Ludmilla Thomé Domingos
Format: Article
Language:English
Subjects:
Growth factors
Head & neck cancer
Immunocytochemistry
Medical prognosis
Metastases
Squamous cell carcinoma
Transforming growth factor-b
Tumor cells
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Circulating tumor microemboli (CTM) are clusters of circulating tumor cells (CTCs), involved in metastasis, as also transforming growth factor-[beta] (TGF-[beta]). The purpose of this study was to verify their role in progression-free survival (PFS). Methods Blood from patients with locally advanced head and neck squamous cell carcinoma (HNSCC; n=53) was analyzed in 2 moments. TGF-[beta] receptor I (TGF-[beta]RI) expression was evaluated by immunocytochemistry. Results Comparing CTM1 (baseline) with CTM2 (first follow-up), patients with CTM1-positive disease who became CTM2-negative were classified as favorable (PFS 20 months). Patients with unfavorable evolution (CTM1-negative/CTM2-positive), had PFS of 17.5 months. Patients always CTM-negative showed PFS of 22.4 months, those always positive, 4.7 months (P
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.24899